Dr. Steven E Nissen and Dr. C. Michael Gibson Discuss: ALPACAR Phase 2 Trial of Zerlasiran: Multiple Doses of a Short-Interfering RNA Targeting Lipoprotein(a) Over 60 weeks. November 18, 2024 2024 | AHA | Cardiology | Trial | Video Nissen, StevenDownload Disclosures: TBD Article Navigation Dr. Rajeev K Pathak and Dr. C. Michael Gibson Discuss: Aggressive Risk Factor Reduction Study for Atrial Fibrillation (ARREST-AF) Implications for Ablation Outcomes: A Randomized Clinical Trial Dr. Stephen Nicholls and Dr. C. Michael Gibson Discuss: A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN)
